Immune Checkpoint Inhibitors versus VEGF Targeted Therapy as Second Line Regimen in Advanced Hepatocellular Carcinoma (HCC): A Retrospective Study

Several targeted agents including multi-tyrosine kinase inhibitors (mTKIs) and immunotherapy (IO) agents have been approved for use beyond the frontline setting in patients with advanced hepatocellular carcinoma (HCC). Due to lack of prospective head-to-head comparative trials, there is no standardi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Med
Main Authors: Saeed, Anwaar, Hildebrand, Hannah, Park, Robin, Al-Jumayli, Mohammed, Abbasi, Saqib, Melancon, Tina, Saeed, Azhar, Al-Rajabi, Raed, Kasi, Anup, Baranda, Joaquina, Williamson, Stephen, Sun, Weijing
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7563439/
https://ncbi.nlm.nih.gov/pubmed/32824968
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm9092682
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados